Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from REGN

Dow Jones Futures Erase Losses On Russia Comments; Market Rally At Key Level

Futures rose with Russia/Ukraine tensions in focus after the stock market rally sold off Friday. Tesla China sales were strong.

Investors Business Daily

Regeneron Scores Quarterly Beat — But How Long Will Its Covid Tailwind Persist?

Regeneron Scores Quarterly Beat — But How Long Will Its Covid Tailwind Persist?

Regeneron snagged a quarterly beat Friday, reporting sales growth almost entirely attributed to its Covid cocktail — and REGN stock rose.

Investors Business Daily

Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales

Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap: Regeneron Pharmaceuticals Q4 Earnings

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Earnings Preview For Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Regeneron Pharmaceuticals will likely report an Earnings Per Share (EPS) of $18.11.

Analyst Ratings For Regeneron Pharmaceuticals

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have

inkl

Read news from The Economist, FT, and more,
with one subscription

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescin

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc

Eli Lilly And Co

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

289,942 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play